Detecting the mutational signature of homologous recombination deficiency in clinical samples

Mutations in BRCA1 and/or BRCA2 ( BRCA1/2 ) are the most common indication of deficiency in the homologous recombination (HR) DNA repair pathway. However, recent genome-wide analyses have shown that the same pattern of mutations found in BRCA1 / 2 -mutant tumors is also present in several other tumors. Here, we present a new computational tool called Signature Multivariate Analysis (SigMA), which can be used to accurately detect the mutational signature associated with HR deficiency from targeted gene panels. Whereas previous methods require whole-genome or whole-exome data, our method detects the HR-deficiency signature even from low mutation counts, by using a likelihood-based measure combined with machine-learning techniques. Cell lines that we identify as HR deficient show a significant response to poly (ADP-ribose) polymerase (PARP) inhibitors; patients with ovarian cancer whom we found to be HR deficient show a significantly longer overall survival with platinum regimens. By enabling panel-based identification of mutational signatures, our method substantially increases the number of patients that may be considered for treatments targeting HR deficiency. Signature Multivariate Analysis is a new computational tool that detects the mutational signature of homologous-recombination deficiency in clinical samples sequenced with targeted panels, enabling the identification of patients who are responsive to poly (ADP-ribose) polymerase inhibition therapy.